Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia

Mark H. Einstein, Yevgeniy Y. Studentsov, Gloria Y F Ho, Melissa Fazzari, Morgan Marks, Anna S. Kadish, Gary L. Goldberg, Carolyn D. Runowicz, Robert D. Burk

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The objective of this study was to assess the utility of a second generation human papillomavirus (HPV) virus-like particle (VLP)-based ELISA as an adjunct to HPV DNA testing to identify women at risk for high-grade cervical intraepithelial neoplasia (CIN). Participants provided blood, cervical samples and interviewer-obtained questionnaire information. HPV VLPs for types 16, 18, 33, 45 and 52 were produced using a baculovirus expression system. These highly purified VLPs were used in a polymer-based ELISA test. Cases with biopsy-confirmed CIN (CIN I, n = 237; CIN II, n = 56; CIN III, n = 48) and controls (n = 351) with normal Pap smears were tested for HPV DNA by PCR and serologic response to multiple oncogenic HPV VLPs. 258/341 (76%) of cases and 230/351 (65.5%) of control patients had any type of HPV VLP antibody (OR = 1.63, 95% CI 1.16-2.30). More cases were seropositive than controls for each individual HPV type (p < 0.001 for HPV types 16, 18, 33 and 45; p = 0.06 for HPV 52). Reactivity to an increasing number of different HPV type-specific VLPs are associated with high-grade CIN independent of HPV DNA status. HPV VLP assays may be useful as an adjunct to HPV DNA testing in a subset of patients that needs to be defined by further studies.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalInternational Journal of Cancer
Volume120
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Cervical Intraepithelial Neoplasia
Papillomaviridae
DNA
Virion
Human papillomavirus 16
Enzyme-Linked Immunosorbent Assay
Papanicolaou Test
Human papillomavirus 18
Baculoviridae
Polymers
Interviews
Biopsy
Polymerase Chain Reaction
Antibodies

Keywords

  • Cervical intraepithelial
  • HPV serology
  • Human papillomavirus
  • Neoplasia
  • Predictors for disease
  • Virus-like particles

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. / Einstein, Mark H.; Studentsov, Yevgeniy Y.; Ho, Gloria Y F; Fazzari, Melissa; Marks, Morgan; Kadish, Anna S.; Goldberg, Gary L.; Runowicz, Carolyn D.; Burk, Robert D.

In: International Journal of Cancer, Vol. 120, No. 1, 01.01.2007, p. 55-59.

Research output: Contribution to journalArticle

Einstein, Mark H. ; Studentsov, Yevgeniy Y. ; Ho, Gloria Y F ; Fazzari, Melissa ; Marks, Morgan ; Kadish, Anna S. ; Goldberg, Gary L. ; Runowicz, Carolyn D. ; Burk, Robert D. / Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. In: International Journal of Cancer. 2007 ; Vol. 120, No. 1. pp. 55-59.
@article{cc8cd277fc2c46dab037dd110a174ff0,
title = "Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia",
abstract = "The objective of this study was to assess the utility of a second generation human papillomavirus (HPV) virus-like particle (VLP)-based ELISA as an adjunct to HPV DNA testing to identify women at risk for high-grade cervical intraepithelial neoplasia (CIN). Participants provided blood, cervical samples and interviewer-obtained questionnaire information. HPV VLPs for types 16, 18, 33, 45 and 52 were produced using a baculovirus expression system. These highly purified VLPs were used in a polymer-based ELISA test. Cases with biopsy-confirmed CIN (CIN I, n = 237; CIN II, n = 56; CIN III, n = 48) and controls (n = 351) with normal Pap smears were tested for HPV DNA by PCR and serologic response to multiple oncogenic HPV VLPs. 258/341 (76{\%}) of cases and 230/351 (65.5{\%}) of control patients had any type of HPV VLP antibody (OR = 1.63, 95{\%} CI 1.16-2.30). More cases were seropositive than controls for each individual HPV type (p < 0.001 for HPV types 16, 18, 33 and 45; p = 0.06 for HPV 52). Reactivity to an increasing number of different HPV type-specific VLPs are associated with high-grade CIN independent of HPV DNA status. HPV VLP assays may be useful as an adjunct to HPV DNA testing in a subset of patients that needs to be defined by further studies.",
keywords = "Cervical intraepithelial, HPV serology, Human papillomavirus, Neoplasia, Predictors for disease, Virus-like particles",
author = "Einstein, {Mark H.} and Studentsov, {Yevgeniy Y.} and Ho, {Gloria Y F} and Melissa Fazzari and Morgan Marks and Kadish, {Anna S.} and Goldberg, {Gary L.} and Runowicz, {Carolyn D.} and Burk, {Robert D.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1002/ijc.22176",
language = "English (US)",
volume = "120",
pages = "55--59",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia

AU - Einstein, Mark H.

AU - Studentsov, Yevgeniy Y.

AU - Ho, Gloria Y F

AU - Fazzari, Melissa

AU - Marks, Morgan

AU - Kadish, Anna S.

AU - Goldberg, Gary L.

AU - Runowicz, Carolyn D.

AU - Burk, Robert D.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The objective of this study was to assess the utility of a second generation human papillomavirus (HPV) virus-like particle (VLP)-based ELISA as an adjunct to HPV DNA testing to identify women at risk for high-grade cervical intraepithelial neoplasia (CIN). Participants provided blood, cervical samples and interviewer-obtained questionnaire information. HPV VLPs for types 16, 18, 33, 45 and 52 were produced using a baculovirus expression system. These highly purified VLPs were used in a polymer-based ELISA test. Cases with biopsy-confirmed CIN (CIN I, n = 237; CIN II, n = 56; CIN III, n = 48) and controls (n = 351) with normal Pap smears were tested for HPV DNA by PCR and serologic response to multiple oncogenic HPV VLPs. 258/341 (76%) of cases and 230/351 (65.5%) of control patients had any type of HPV VLP antibody (OR = 1.63, 95% CI 1.16-2.30). More cases were seropositive than controls for each individual HPV type (p < 0.001 for HPV types 16, 18, 33 and 45; p = 0.06 for HPV 52). Reactivity to an increasing number of different HPV type-specific VLPs are associated with high-grade CIN independent of HPV DNA status. HPV VLP assays may be useful as an adjunct to HPV DNA testing in a subset of patients that needs to be defined by further studies.

AB - The objective of this study was to assess the utility of a second generation human papillomavirus (HPV) virus-like particle (VLP)-based ELISA as an adjunct to HPV DNA testing to identify women at risk for high-grade cervical intraepithelial neoplasia (CIN). Participants provided blood, cervical samples and interviewer-obtained questionnaire information. HPV VLPs for types 16, 18, 33, 45 and 52 were produced using a baculovirus expression system. These highly purified VLPs were used in a polymer-based ELISA test. Cases with biopsy-confirmed CIN (CIN I, n = 237; CIN II, n = 56; CIN III, n = 48) and controls (n = 351) with normal Pap smears were tested for HPV DNA by PCR and serologic response to multiple oncogenic HPV VLPs. 258/341 (76%) of cases and 230/351 (65.5%) of control patients had any type of HPV VLP antibody (OR = 1.63, 95% CI 1.16-2.30). More cases were seropositive than controls for each individual HPV type (p < 0.001 for HPV types 16, 18, 33 and 45; p = 0.06 for HPV 52). Reactivity to an increasing number of different HPV type-specific VLPs are associated with high-grade CIN independent of HPV DNA status. HPV VLP assays may be useful as an adjunct to HPV DNA testing in a subset of patients that needs to be defined by further studies.

KW - Cervical intraepithelial

KW - HPV serology

KW - Human papillomavirus

KW - Neoplasia

KW - Predictors for disease

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=33845429485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845429485&partnerID=8YFLogxK

U2 - 10.1002/ijc.22176

DO - 10.1002/ijc.22176

M3 - Article

VL - 120

SP - 55

EP - 59

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -